Response to letter: “Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule” by Suzuki et al - Ihara, Keiko; Ohtani, Seiya; Watanabe, Narumi; Takahashi, Nobuyuki; Hori, Satoko; Nakahara, Jin; Takizawa, Tsubasa (Journal of the neurological sciences, 2023)
Keywords: Anti-calcitonin gene-related peptide monoclonal antibodies; Fremanezumab; Galcanezumab; Migraine; Neurology; Switch; Fremanezumab; Switch; MMD; Migraine; anti-CGRP mAbs; Anti-calcitonin gene-related peptide monoclonal antibodies; Galcanezumab; monthly migraine days